GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Cabotegravir - APRETUDE intramuscular injection

Local official-label summaryBase record retrieved 2026-09-10See the evidence for this drug2 sources available - open source summaries, references and comparisons

APRETUDE / cabotegravir PrEP

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Prevention and combination HIV treatment have different renal wording

APRETUDE and CABENUVA are not interchangeable products. HIV testing remains essential before each APRETUDE injection.

Before applying: Confirm the product, indication and acute-infection testing. Do not infer a dialysis supplement from protein binding.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

APRETUDE - cabotegravir kit

Product / population
APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.
Renal measure
CrCl, mL/min; source subsection does not name an equation

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections checked. Raw SPL XML, original document hash and complete revision history were not obtained.

Renal dosing, restrictions and evidence limits

No renal adjustment is required at CrCl 15 to below 90 mL/min, based on studies of oral cabotegravir. The effects in ESRD without dialysis are unknown. High protein binding makes dialysis unlikely to alter exposure; this does not establish a supplemental dialysis dose.

Confirm negative HIV-1 status before initiation and before every injection using testing appropriate for acute/primary infection. APRETUDE is prevention, not a complete treatment regimen for established HIV-1. Apply the full eligibility and missed-injection instructions separately.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4338428e-43d4-4e02-ac9d-bd98e738a7da

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

APRETUDE - cabotegravir kit

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.

Renal method: CrCl, mL/min; source subsection does not name an equation
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - APRETUDE

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.

Renal method: CrCl, mL/min; equation not named in selected renal section
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Prevention and combination HIV treatment have different renal wording

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

product and indication

Prevention and combination HIV treatment have different renal wording

APRETUDE and CABENUVA are not interchangeable products. HIV testing remains essential before each APRETUDE injection.

How to use this: Confirm the product, indication and acute-infection testing. Do not infer a dialysis supplement from protein binding.

GlobalRPh RX List - APRETUDEAPRETUDE - cabotegravir kitCabotegravir / rilpivirine - CABENUVA intramuscular kit

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAPRETUDE - cabotegravir kitGlobalRPh RX List - APRETUDE
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/apretude-drug/

Exact product and population

APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.

RDM57-SCOPE-cabotegravir-apretude · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

APRETUDE - cabotegravir kit

Open original reference

Open / share this exact local source

DailyMed / ViiV Healthcare Company · APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.

Renal method: CrCl, mL/min; source subsection does not name an equation
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No renal adjustment is required at CrCl 15 to below 90 mL/min, based on studies of oral cabotegravir. The effects in ESRD without dialysis are unknown. High protein binding makes dialysis unlikely to alter exposure; this does not establish a supplemental dialysis dose.

Confirm negative HIV-1 status before initiation and before every injection using testing appropriate for acute/primary infection. APRETUDE is prevention, not a complete treatment regimen for established HIV-1. Apply the full eligibility and missed-injection instructions separately.

RDM57-official-cabotegravir-apretude-ce1fc63ae7-C1 · Source locator: Boxed warning; Sections 1, 2.2, 8.6 and 12.3

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

Exact DailyMed HTML identity and named sections checked. Raw SPL XML, original document hash and complete revision history were not obtained.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4338428e-43d4-4e02-ac9d-bd98e738a7da
Retrieved
2026-09-10
Exact label title
APRETUDE - cabotegravir kit
DailyMed Set ID
4338428e-43d4-4e02-ac9d-bd98e738a7da
Labeler
ViiV Healthcare Company
Renal-function method
CrCl, mL/min; source subsection does not name an equation
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
3b0100d95fcd8cb4ef524d460fe58402e86bb78e7d2218017a272ceac1e36cec
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - APRETUDE

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · APRETUDE long-acting intramuscular cabotegravir for HIV-1 PrEP; not CABENUVA HIV treatment.

Renal method: CrCl, mL/min; equation not named in selected renal section
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The selected renal paragraph requires no adjustment at CrCl 15 to below 90 mL/min, based on oral cabotegravir studies. ESRD without dialysis has unknown PK. Dialysis is not expected to change exposure because protein binding is high; this is a pharmacologic expectation, not a dedicated dialysis dosing study.

Do not transfer the statement to cabotegravir/rilpivirine combination therapy. HIV-negative status and the product-specific testing requirements remain essential for PrEP.

RDM57-rxlist-cabotegravir-apretude-fc41b9db62-C1 · Source locator: Selected renal impairment, dosing and precautions sections

Source-specific limits

Selected sections only; not a complete prescribing monograph or independent clinician approval.

The hosted label mirror is not independent corroboration of its underlying label. Official-label confirmation of this new card remains pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/apretude-drug/
Retrieved
2026-09-10
Renal-function method
CrCl, mL/min; equation not named in selected renal section
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
a7a28babdc3da3a3fc2d2bc3bc0be3ca5b91008b60ac8661365b82a87cdf70ed

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/apretude-drug/
Source retrieval
2026-09-10. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
8813082534b57cec57d59bbc40abde5925104743108018c1dd59d34edc1d5191
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report